Surgical skills and facts may be best taught in non-clinical training modules
Editor-Moorthy et al highlight the need to assess surgical trainees' skills reliably and accurately, outlining options available to achieve this end. 1 Inadequate objective skill based assessment and poor knowledge of basic science are major concerns for both trainers and trainees alike.
However, the context in which skills and facts are acquired is just as important as method of assessment. Basic and higher surgical training are currently clinically based, supplemented by courses, educational meetings, and tutorials.
Unfortunately, many trainees attend the course for basic surgical skills well into their training. Some partially fund such courses because of limited deanery budgets or are denied study leave because of service commitments. Training schemes seldom offer revision of anatomy or physiology in the dissection room or laboratory from basic science staff.
In contrast, trainee chartered accountants enjoy the benefit of several structured, month long, free courses between work placements. Pass rates exceed comparable surgical examinations, and trainees receive useful career preparation.
The surgical royal colleges acknowledge that training needs restructuring. 2 I suggest that protected, structured blocks of teaching and assessing basic sciences and skills should be provided throughout surgical training. Proposed changes to training present an ideal opportunity to implement such modules. 3 Objections are predictable. It would be costly. Trainees would require release from some service commitments. Postgraduate training would have to be properly organised. Difficulties arise in the objective assessment of trainees. 4 But if surgical teaching and assessment is to improve then the solution must be more radical than formulating another three day course, or adding an extra examination. 
Treating inguinal hernias
Editorial does not tell the whole story. . .
Editor-In his editorial Kingsnorth argues that open inguinal hernia repair with the
Lichtenstein method is superior to the laparoscopic approach. 1 We think that this is not the whole story.
In a recent Cochrane review six visceral and seven vascular injuries (in 2498 patients) were reported in the laparoscopic group compared with one and five (in 2758 patients) in the open group. 2 In the laparoscopic group the convalescence was significantly shorter than after open surgery (7 days, P < 0.001). Furthermore, and probably most importantly, the review found a significant reduction in the rate of chronic groin pain (290/2101 v 459/2399, P < 0.001) after laparoscopic repair, with no difference in recurrence rates after the two procedures.
Although the direct cost of the laparoscopic technique is higher, this difference is eliminated by recommending a convalescence of one week only. 3 Kingsnorth's concern about the complex nature of the laparoscopic procedure is legitimate, but, as the learning curve is 30-50 operations, 4 this problem can be solved by establishing dedicated centres for laparoscopic hernia repair, as is commonly done in many countries when the Lichtenstein procedure is the preferred method.
Laparoscopic hernia repair is not a dangerous procedure. The learning curve can be facilitated by establishing laparoscopic hernia centres, and the cost can be reduced effectively and equalised with the open procedure. Most importantly, laparoscopic hernia repair is followed by much less pain, and this must be one of the top priorities of a responsible surgeon. community and the National Institute for Clinical Excellence (NICE).
Kingsnorth reports that the incidence of chronic groin pain after hernia repair has now overtaken that of hernia recurrence, without making it clear that among the various advantages of laparoscopic hernia repair (less postoperative pain and earlier return to normal activity) chronic groin pain almost never occurs.
The rare but serious complications that he quotes from the European Union's hernia trialists collaboration were for transabdominal pre-peritoneal hernia repairs (as opposed to totally extra peritoneal repairs), 2 which are not currently recommended by NICE.
The article did not highlight the fact that laparoscopic repair is recommended by NICE for bilateral and recurrent hernia repair. The main objections to laparoscopic repair for primary hernias are apparently financial and not clinical. 3 Interestingly the illustration of mesh in the preperitoneal space is the mesh place- 
Author's reply
Editor-Øberg and Rosenberg are keen protagonists of the laparoscopic operation for treating inguinal hernias and propose the establishment of dedicated laparoscopic hernia centres. To train surgeons in one operation in specialised units is clearly impracticable and is not cost effective. It will take a long time to train a cohort of surgeons proficient in laparoscopic herniorrhaphy on the basis of the data of Bittner et al, who reported over 8000 laparoscopic repairs in eight years, during which they were able to train only eight junior surgeons. 1 The average general surgeon will repair only 30-40 inguinal hernias yearly. Enthusiastic laparoscopic surgeons, however, are strident in their demands for other surgeons to be converted to this operation with its long learning curve.
DeTurris et al, in analysing 38 randomised trials, concluded that their analysis failed to make a convincing case for the superiority of either open or laparoscopic herniorrhaphy, which includes operative time, postoperative pain, return to work, complications, and recurrences. 2 Peyser's letter is riddled with misleading and inaccurate information. Laparoscopic herniorrhaphy has been largely dismissed by the surgical community: 96% of UK surgeons, 86% of US surgeons, and virtually all Japanese surgeons use open repair. [3] [4] [5] There are no hard data for European countries, but in France laparoscopic repair is rapidly declining following guidance from the French equivalent of the National Institute for Clinical Excellence.
Regarding chronic groin pain, the EU Hernia Trials Collaboration has pointed out the large confidence intervals in its analysis and has indicated that a large randomised controlled trial is needed, with specific end points to arrive at definitive conclusions.
The illustration in my editorial and here is for an open mesh placed by the preperitoneal route, as described by Stoppa ( figure) . The Plymouth Hernia Service not only supports my practice of open inguinal herniorrhaphy but also that of three of my colleagues who undertake laparoscopic repair for bilateral and recurrent inguinal hernias and incisional hernias. 
Andrew Kingsnorth professor of surgery

Prevention of coronary heart disease
Statins are even less effective than paper shows
Editor-Marshall commendably questions current trends in preventive medicine. 1 He looks at cost effectiveness of cardioprotective drug treatment, including simvastatin 40 mg, by assessing pooled data from different trials. Treatment effects are balanced with costs. The expenditure for simvastatin 40 mg is calculated as prescribing costs plus additional costs for administration and laboratory tests.
A close look at the heart protection study, 2 3 Marshall's main reference for statins, quickly calls this equation into question. Simvastatin 40mg was less well tolerated and less effective than portrayed by the authors.
Firstly, tolerability: against all claims simvastatin was not well tolerated. A substantial number of patients did not enter the trial after a six week run in before randomisation (63 603 entered the original screening, 32 145 went forward to the run in phase and 11 609 patients dropped out then).
Secondly, independent treatment effects: Marshall assumes that statins work independently of other cardioprotective treatment as stated in the heart protection study. However, most of the patients in the study did not take appropriate non-statin drug treatment-for example, only 47% of all patients with peripheral vascular disease were taking aspirin.
Thirdly, reduced treatment effects for women: simvastatin in the heart protection study did not reduce overall mortality in women. 4 This fact was buried by the researchers using composite end points.
Marshall questions the cost effectiveness of different cardiovascular treatments including statins. The properly interpreted results of the heart protection study lend even more weight to his scepticism. Placement of mesh into the periperitoneal space with wide overlap to prevent recurrence
Is a cure too expensive?
Editor-As Warburton points out in her editorial, we may soon be able to reduce the event rate in patients at risk of coronary heart disease to towards zero. 1 The current cocktail of drugs is likely to decrease events by up to 88%. 2 We have been fortunate that most of the drugs in this cocktail are cheap (aspirin, thiazides, blockers). Marshall in his article shows that aspirin (NHS price £0.18 per 28 days) is much more cost effective than clopidogrel (NHS price £35.31 per 28 days) and statins (NHS price £29.68 per 28 days). 3 I doubt that anybody would have been surprised by this finding.
If we continue to pursue new treatments that will reduce the risks of ischaemic heart disease further they will inevitably be much less cost effective than aspirin. As the event rate goes down with each successful intervention the number needed to treat for each new drug will increase. If we follow the logic expressed in this article then we should give up trying as nothing will ever be as cost effective as aspirin.
The effective cure of the biggest killer in the Western world would have been a triumph for mankind, medicine, and big pharma. It seems that, like going to the moon, it isn't going to be very cost effective. 
Incremental cost effectiveness raises issues
Editor-Marshall seemed not to include the cost to the health system of treatment after a myocardial infarction occurs. 1 You could go further and estimate the cost to society of prematurely losing productive members. Say, for example, one myocardial infarction was prevented with treatment A and two with treatment B in a group of 100. If A costs $1 a year and B, $10, then A would be five times as cost effective as B per event prevented. However, if the cost of treatment after an event occurs is high, B could be more cost effective. If they operate independently A and B together could be the best treatment.
Marshall might have discussed what dosages of statins were used. In the United States the cost is fairly constant with dose, but the effectiveness for a given patient could change and so would the cost effectiveness.
Marshall assumed a patient (pretreatment) had a 10% risk of a coronary event over five years-which seems low for a patient seeing a cardiologist-and then applied a relative risk based on other studies. On the basis of a meta-analysis of other studies, out of 100 people who would have had a coronary event, 69 would have been taking a statin, 72 aspirin, and 50 both.
A 10% risk of a coronary event biases the results towards the lower cost treatment. If you picked a group with an extremely low chance of a coronary event over five years the cheaper treatment would be quite cost effective. Furthermore, were the aspirin and statin groups similar and were they at 10% coronary risk?
To treat patients at lower risk slightly more aggressively is appropriate. Some, however, might conclude from this study that this might have been done at the expense of those at higher risk or by choosing either statins or aspirin but not both. 
William C D'Avanzo
Data in table 2 could be shown more explicitly for better understanding
Editor-The cost effectiveness study published by Marshall is difficult to understand in its technical details not only by average readers but also people with some skill in pharmacoeconomics. 1 We think that the part of this study that presents the data of the average cost effectiveness (table 1 of the article) is useless because the practical implications of this study, along with the assessment of the pharmacoeconomic profile of the various drugs, rely exclusively on the findings of the incremental cost effectiveness analysis (the data presented in table 2). Table 2 is not adequately explained by the author. For this reason, we propose a more detailed layout, in which much more information is presented and the labelling of each row is made more explicit (see bmj.com). 
Author's reply
Editor-Correspondents responding to my article on bmj.com raise several interesting issues. 1 Nevertheless no correspondent disputes either the approach (incremental cost effectiveness analysis) or the fundamental findings: that aspirin and antihypertensive treatment with bendrofluazide and atenolol are markedly more cost effective than statins and clopidogrel. Conradi et al and O'Donnell indicate that statins may have more side effects than is generally appreciated. Mann doubts the effectiveness of clopidogrel in primary prevention. 1 Both points strengthen the paper's conclusions. I agree with Mann's suggestion that individuals need information on the risk reduction with treatment in order to decide if it is worth while.
Cooke says that the development of further drugs to prevent coronary heart disease may not be cost effective. It is very efficient to prevent coronary disease by using existing, low cost treatments.
If, as Jacobs says, treatment effects are not independent, second and third treatments may be even less cost effective than the analysis shows. 1 Under current criteria, 80% of those eligible for one preventive treatment are eligible for at least two and 53% are eligible for all three.
Das and Vos suggest oily fish as an intervention. 1 Wide confidence intervals around the estimated effectiveness of dietary oily fish meant it was excluded from the published paper, however it is probably more cost effective than a statin.
Mihaylova et al suggest further refinements to the model including cost savings from heart disease prevented. They acknowledge that these refinements are unlikely to affect the rankings or overall message. 1 As the purpose of economic evaluation is to improve decision making it is not clear how further complexity can be justified in terms of better decisions. My analysis includes sufficient information to improve decision making dramatically within preventive cardiology. Complex analysis is not always well understood. 2 Several correspondents refer to an imminent fall in the price of simvastatin. At £4.45 a pack (containing 28 tablets), simvastatin becomes the third most cost effective intervention. Under these circumstances a rational policy would offer aspirin at 5% coronary risk, bendrofluazide and atenolol at 7.5%, and simvastatin at 15%. A third Cost effectiveness of preventive treatments (£) in patients at different degrees of risk if price of simvastatin falls by 85% 
Payment for coroners' postmortem examinations
Financial gain is pathetic . . .
Editor-Alcolado remembers as a house officer requesting a postmortem examination and being forced to make it a coroner's at the request of a pathologist. 1 Firstly, let me make it clear that nobody can force someone to make a death into a coroner's post mortem if a cause of death is established. The doctor simply signs the death certificate to this effect. I know of no pathologist who can bend the ear of the coroner to this extent-rather the opposite. In my experience, cases are often not referred to the coroner that should be, such as postoperative deaths.
Secondly, the idea that the pathologist receives "a substantial payment" for each coroner's post mortem is laughable. I get £78 for each postmortem case I do, and this often involves four to six hours of work because I deal with complex postoperative deaths that usually require detailed examination and histology. The BMA is looking into the fees for coroners' autopsies and campaigning for a substantial increase. The pathologist who forced Alcolado to turn a case into a coroner's post mortem must have been desperate to waste his or her precious time for £78.
Finally, all coroners' cases in my hospital are actively used for teaching and audit purposes. 
. . . and not part of the equation
Editor-Alcolado in his letter describes a consultant pathologist insisting that a case be referred to the coroner for an autopsy, and he implies that this was for financial gain (which, from his account, seems possible). 1 Such behaviour by any of the six consultants in my department would be completely unacceptable, and I am sure that most histopathologists in the United Kingdom would agree. His suggestion that financial gain be taken out of the equation could perhaps be applied to many fields of medicine, although the new contract would imply that this is not current policy.
I would gladly stop doing my extracontractual coroners' work and forgo the comparatively small income derived from it. We have recently turned down the offer of an increase in this work, despite what Alcolado views as the "substantial payment" offered.
Simon Rose consultant histopathologist
Royal United Hospital, Bath BA1 3NR simon.rose@ruh-bath.swest.nhs.uk
Omega 3 fatty acids and cardiovascular disease
Algae can be source of "fish" oil
Editor-Concern about depletion of fish stocks will not be addressed by supplementing animal feed with fish oil, as suggested by Din et al, 1 because this requires the harvesting of wild fish to provide the fish oil. Fish farming does not provide a solution as farmed fish contains fewer omega 3 fatty acids, this being dependent on what they are fed-usually wild caught fish products. 2 The original source of the long chain omega 3 fatty acids found in fish is, however, the chloroplasts of marine algae and phytoplankton at the bottom of the food chain. 3 In the marine environment polyunsaturated fatty acids may provide the degree of desaturation needed to keep cell membranes fluid in cold water. Rather than genetically modifying terrestrial plants to produce eicosapentaenoic and docosahexanoic acid, marine algae can be cultured industrially to provide the "fish" oil while leaving the fish alone. 4 If cod liver oil is used as a source of fish oil it is important to remember that this contains a comparatively high concentration of vitamin A, producing a risk of toxicity. 5
Matthew D Barber specialist registrar in general surgery
Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU barbermd@hotmail.com absolute amount of omega 3 per gram of fish is the more relevant figure.
Supplementation of animal feed with fish oils will not address concerns about the depletion of fish stocks since this will clearly entail the harvesting of even more fish. However, we wanted to highlight that this is a potential approach to increase the dietary consumption of omega 3 oils in people unwilling or unable to eat fish. We acknowledge that the juxtaposition of these two independent points in the text box is rather misleading.
We intentionally focused our article on the marine derived omega 3 fatty acids because of the larger and clearer evidence base. We cannot assume that linolenic acid confers the same benefits as it is a structurally distinct short chain polyunsaturated fatty acid with only limited conversion in humans to the longer chain eicosapentanoic acid and docosahexanoic acid. 2 Whereas linolenic acid may confer cardiac protection as part of a Mediterranean diet, 3 the direct benefits of linolenic acid have not been firmly established. We agree that ongoing concerns about fish stocks highlight the need for further trials of linolenic acid in coronary heart disease. Competing interests: None declared.
Making Amends misses the point
Editor-Making Amends says that NHS staff should inform patients of negligent acts. 1 2 The chief medical officer's sweetening of the proposed duty of candour with an exemption from disciplinary action if reporting issues of patient safety is well intentioned but wrong. Every doctor tries to do his or her best to provide good quality care to his or her patients. As doctors, we would be insulted if people were to think that we need to be made less accountable for us to do what any responsible professional should, which is to act in the best interests of patients. Reporting adverse events and errors so that these can be investigated when necessary, and learnt from when possible, is clearly in the best interests of patients' safety.
Of course, it would help secure the maximum compliance with reporting procedure if health professionals could have confidence that when reporting adverse events and near misses they would not face unreasonable consequences as a result. That is already a principle supported by patients' and doctors' groups alike, and an integral part of the "charter of understanding between doctors and people affected by medical accidents," which the charity Action Against Medical Accidents (AvMA) launched with our assistance last year.
We strongly endorse the charity's view that an open and fair culture can be achieved without sacrificing professional accountability or damaging public confidence by providing unnecessary and inappropriate exemptions. Growing support for the charter of understanding and the emerging success of new initiatives to help maintain standards, such as the National Clinical Assessment Authority, which offers retraining to underperforming doctors before suspension becomes an issue, are reassuring signs that a fairer more open culture in medicine is developing.
